Cargando…
Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
BACKGROUND: Studies have shown increased gastric cancer risk in users of proton pump inhibitors (PPI) and histamine-2 receptor antagonists, questioning the safety of gastric acid suppression. Therefore, we conducted a case–control study within the Scottish Primary Care Clinical Informatics Unit (PCC...
Autores principales: | Liu, Peipei, McMenamin, Úna C., Johnston, Brian T., Murchie, Peter, Iversen, Lisa, Lee, Amanda J., Vissers, Pauline A. J., Cardwell, Chris R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374738/ https://www.ncbi.nlm.nih.gov/pubmed/32367073 http://dx.doi.org/10.1038/s41416-020-0860-4 |
Ejemplares similares
-
Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study
por: Liu, Peipei, et al.
Publicado: (2019) -
Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review
por: Spence, Andrew D., et al.
Publicado: (2017) -
Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?
por: Tomita, Toshihiko, et al.
Publicado: (2011) -
Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease: a protocol for a cohort study from Scotland and Wales
por: McMenamin, Úna, et al.
Publicado: (2021) -
Association of proton pump inhibitor and histamine H(2)-receptor antagonists with restless legs syndrome
por: Earley, Eric J, et al.
Publicado: (2020)